Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer
- PMID: 33889204
- PMCID: PMC8043684
- DOI: 10.3332/ecancer.2021.1195
Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer
Abstract
Oesophageal cancer is among the ten most common types of cancer worldwide. More than 80% of the cases and deaths related to the disease occur in developing countries. Local socio-economic, epidemiologic and healthcare particularities led us to create a Brazilian guideline for the management of oesophageal and oesophagogastric junction (OGJ) carcinomas. The Brazilian Group of Gastrointestinal Tumours invited 50 physicians with different backgrounds, including radiology, pathology, endoscopy, nuclear medicine, genetics, oncological surgery, radiotherapy and clinical oncology, to collaborate. This document was prepared based on an extensive review of topics related to heredity, diagnosis, staging, pathology, endoscopy, surgery, radiation, systemic therapy (including checkpoint inhibitors) and follow-up, which was followed by presentation, discussion and voting by the panel members. It provides updated evidence-based recommendations to guide clinical management of oesophageal and OGJ carcinomas in several scenarios and clinical settings.
Keywords: gastroesophageal cancer; guidelines; oesophageal cancer.
© the authors; licensee ecancermedicalscience.
Conflict of interest statement
Duilio R Rocha-Filho: personal fees from Bayer, Merck Serono and Servier. Renata D’Alpino Peixoto: personal fees from Lilly and MSD. Anelisa K Coutinho: personal fees from Amgen, Bayer, Roche, MSD, Merck Serono, Sanofi, Servier, Ipsen, Novartis and United Medical. Juliana F M Rego: personal fees from Novartis, Bayer, Amgen and Ipsen. Rachel Riechelmann: research grants from Libbs (gastric consensus only). Rui F Weschenfelder: personal fees from Lilly, MSD and Roche. Alexandre A Jacome: personal fees from Roche, Novartis, Zodiac and Pfizer. Research grants from Bayer. Celso A L Mello: personal fees from Lilly, Merck Serono, MSD and Roche. Gustavo S Fernandes: personal fees from BMS, Bayer and Roche. Roberto A Gil: personal fees from Amgen, Bayer, Lilly, Merck Serono, Roche, Sanofi and United Medical. Research grant from Amgen, Bayer, Merck and Roche. Victor Hugo F Jesus: personal fees from United Medical.
References
-
- INCA. Estimativa 2020: Incidência de câncer no Brasil. Rio de Janeiro: Instituto Nacional de Câncer José Alencar Gomes Da Silva; 2019.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources